2010, Number 1
<< Back Next >>
Rev Hematol Mex 2010; 11 (1)
The effect of autologous hematopoietic stem cell transplantation in nerve conduction velocity in patients with type 2 diabetes mellitus
Lavalle-González FJ, Villarreal-Pérez JZ, Zapata-Garrido AJ, Gómez-Almaguer D, Gutiérrez-Aguirre CH, Mancillas-Adame LG
Language: Spanish
References: 11
Page: 21-24
PDF size: 58.30 Kb.
ABSTRACT
Background: To evaluate the effect of autologous hematopoietic CD34+ cell transplantation (HCT) on diabetic neuropathy in patients with type 2 diabetes mellitus.
Materials and Methods: We recruited ambulatory patients with type 2 diabetes and diabetic neuropathy as defined by the consensus of San Antonio without other active comorbidities. After s.c. filgrastim administration for 4 days, patients were randomized to a treatment group (intervened with autologous intramuscular HCT on the gastrocnemius region) or to a placebo group (intervened with autologous intramuscular plasma on the same region). Patients were evaluated by blinded personnel at the beginning and 3 months later by nerve conduction velocities (NCV) of lower extremities. Successful outcomes were defined as an improvement in NCV.
Results: Twenty patients were included, 15 in the treatment group and 5 in the placebo group. Both groups had successful outcomes in the left peroneal NCV, independent of the number of CD34+ cells transplanted. The differences between groups were not statistically significant.
Conclusions: Although we found improvement in NCV with autologous HCT, we propose further studies to determine the effect of transplantation on diabetic neuropathy.
REFERENCES
Arredondo A, Zúñiga A: Economic consequences of epidemiological changes in diabetes in middle-income countries: the Mexican case (2004) Diabetes Care 27:104-9.
Fact sheet no. 312 of the World Health Organization. Diabetes. [Article online], 2006. Available from http://www.who.int/mediacentre/factsheets/en, accessed 16 June 2008.
Bloomgarden ZT. American Diabetes Association 60th Scientific Sessions, 2000: the diabetic foot (2001) Diabetes Care 24:946-51.
Boulton AJM, Malik RA, Arezzo JC, Sosenko JM: Diabetic somatic neuropathies (2004) Diabetes Care 27:1458-86.
Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC et al.: Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes (2004) Diabetes 53:195-99.
Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC: Autologous transplantation of granulocyte colony–stimulating factor mobilized peripheral blood mononuclear cells improves critical limb ischemia (2005) Diabetes Care 28:2155-60.
Levy BI: Diabetes and ischemia of lower extremities: potential strategies of therapeutic angiogenesis (2005) Journ Annu Diabetol Hotel Dieu:27-32.
Silvestre JS: Diabetes and peripheral arterial occlusive disease: therapeutic potential and pro-angiogenic strategies (2006) Ann Cardiol Angiol 55:100-3.
Hasegawa T, Kosaki A, Shimizu K, Matsubara H, Mori Y, Masaki H et al.: Amelioration of diabetic peripheral neuropathy by implantation of hematopoietic mononuclear cells in streptozotocin-induced diabetic rats (2006) Exp Neurol 199:274-80.
Martinez-Serrano A, Rubio FJ, Navarro B, Bueno C, Villa A: Human neural stem and progenitor cells: In vitro and in vivo properties, and potential for gene therapy and cell replacement in the CNS (2001) Curr Gene Ther 1:279-99.
Mezey É, Chandross KJ, Harta G, Maki RA, McKercher SR: Turning blood into brain: Cells bearing neuronal antigens generated in vivo from bone marrow (2000) Science 290:1779-82.